Adaptive Biotechnologies said it will shed its immune medicine business and offer up to $287.5 million in senior notes, aiming to recalibrate toward its MRD-focused platform. The company expects to provide more detail around the separation plan by the end of the year, while directing the capital strategy to support execution through major program milestones. The restructuring highlights how market pressure is reshaping corporate portfolios, with investors favoring clearer value drivers and platform narratives over early-stage exposure to competitive immunology pipelines. For the MRD community, the company’s shift may accelerate investment in MRD-related assay development and clinical validation as a primary differentiator for minimal residual disease detection and monitoring.